{"id":"double-blind-abatacept","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Infections (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-8","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept works by interrupting the second signal required for full T-cell activation. It consists of the extracellular domain of CTLA-4 fused to the Fc portion of IgG1, allowing it to bind CD80 and CD86 molecules on antigen-presenting cells. This prevents the interaction between these molecules and CD28 on T cells, effectively dampening the adaptive immune response and reducing autoimmune inflammation.","oneSentence":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:50.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT04925375","phase":"PHASE2","title":"Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-07-14","conditions":"Interstitial Lung Disease, Common Variable Immunodeficiency","enrollment":38},{"nctId":"NCT05335928","phase":"PHASE3","title":"Abatacept in Immune Checkpoint Inhibitor Myocarditis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-07-02","conditions":"Myocarditis Acute, Cancer","enrollment":390},{"nctId":"NCT04872218","phase":"PHASE2","title":"Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy","status":"COMPLETED","sponsor":"Philippe Bégin","startDate":"2022-03-01","conditions":"Peanut Allergy","enrollment":14},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT04186871","phase":"PHASE2","title":"Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-07","conditions":"Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus","enrollment":119},{"nctId":"NCT03733067","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-30","conditions":"CTLA4 Haploinsufficency, Chronic Cytopenia","enrollment":""},{"nctId":"NCT06126042","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route","status":"UNKNOWN","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2023-10-03","conditions":"Rheumatoid Arthritis","enrollment":330},{"nctId":"NCT02971683","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-04","conditions":"Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy","enrollment":149},{"nctId":"NCT04472494","phase":"PHASE2","title":"Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-10-14","conditions":"COVID-19, SARS-CoV-2","enrollment":61},{"nctId":"NCT01860976","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-17","conditions":"Psoriatic Arthritis","enrollment":489},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT02270957","phase":"PHASE2","title":"Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2014-01","conditions":"Systemic Lupus Erythematosus","enrollment":66},{"nctId":"NCT02504268","phase":"PHASE3","title":"Effects of Abatacept in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-03","conditions":"Rheumatoid Arthritis","enrollment":994},{"nctId":"NCT02592798","phase":"PHASE2","title":"Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-09","conditions":"Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":36},{"nctId":"NCT01714817","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-22","conditions":"Lupus Nephritis","enrollment":695},{"nctId":"NCT02053727","phase":"NA","title":"Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2014-07","conditions":"Rheumatoid Arthritis, Chronic Hepatitis B","enrollment":""},{"nctId":"NCT02915159","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-12-06","conditions":"Sjogrens Disease","enrollment":250},{"nctId":"NCT02161406","phase":"PHASE2","title":"A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Dinesh Khanna, MD, MS","startDate":"2014-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":88},{"nctId":"NCT02067910","phase":"PHASE3","title":"Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2014-08","conditions":"Sjögren's Syndrome","enrollment":80},{"nctId":"NCT00556439","phase":"PHASE2","title":"Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2008-12","conditions":"Takayasu's Arteritis, Giant Cell Arteritis","enrollment":97},{"nctId":"NCT02923583","phase":"PHASE1","title":"Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-10","conditions":"Healthy Volunteers","enrollment":243},{"nctId":"NCT03192969","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-15","conditions":"Giant Cell Arteritis","enrollment":""},{"nctId":"NCT01758198","phase":"PHASE4","title":"Abatacept Post-marketing Clinical Study in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04-11","conditions":"Rheumatoid Arthritis","enrollment":405},{"nctId":"NCT00095173","phase":"PHASE3","title":"BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-12","conditions":"Juvenile Rheumatoid Arthritis","enrollment":214},{"nctId":"NCT02805010","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":22},{"nctId":"NCT00279760","phase":"PHASE1, PHASE2","title":"Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT01116427","phase":"PHASE2","title":"A Cooperative Clinical Study of Abatacept in Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":65},{"nctId":"NCT02722694","phase":"PHASE3","title":"A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":360},{"nctId":"NCT01350804","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":551},{"nctId":"NCT00774852","phase":"PHASE2","title":"Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Lupus Nephritis, Lupus Erythematosus, Systemic","enrollment":137},{"nctId":"NCT00559585","phase":"PHASE3","title":"Methotrexate-Inadequate Response Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":2492},{"nctId":"NCT01844895","phase":"PHASE3","title":"Methotrexate-Inadequate Response Autoinjector Device Sub Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431},{"nctId":"NCT00430677","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Systemic Lupus Erythematosus","enrollment":423},{"nctId":"NCT00119678","phase":"PHASE2","title":"Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":183},{"nctId":"NCT01917058","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-08","conditions":"Alopecia Areata","enrollment":""},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT00409838","phase":"PHASE3","title":"A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Rheumatoid Arthritis","enrollment":113},{"nctId":"NCT00705367","phase":"PHASE1","title":"Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Lupus Nephritis","enrollment":13},{"nctId":"NCT01314495","phase":"PHASE2","title":"Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis","status":"WITHDRAWN","sponsor":"Julian M. Mackay-Wiggan","startDate":"2011-09","conditions":"Alopecia Totalis/Universalis","enrollment":""},{"nctId":"NCT00534313","phase":"PHASE2","title":"Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Psoriatic Arthritis","enrollment":191},{"nctId":"NCT00162266","phase":"PHASE2","title":"Abatacept With Methotrexate- Phase IIB","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":524},{"nctId":"NCT00420199","phase":"PHASE3","title":"A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-05","conditions":"Active Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT01173120","phase":"PHASE3","title":"Methotrexate - Inadequate Response Device Sub-Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-11","conditions":"Rheumatoid Arthritis (RA)","enrollment":62},{"nctId":"NCT00048568","phase":"PHASE3","title":"A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1250},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT00048581","phase":"PHASE3","title":"Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":738},{"nctId":"NCT00989235","phase":"PHASE3","title":"Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT00287547","phase":"PHASE2","title":"Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1997-03","conditions":"Psoriasis Vulgaris","enrollment":144},{"nctId":"NCT00345748","phase":"PHASE2","title":"A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Rheumatoid Arthritis","enrollment":194},{"nctId":"NCT00277225","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1995-11","conditions":"Psoriasis Vulgaris","enrollment":32},{"nctId":"NCT00035529","phase":"PHASE2","title":"A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00162279","phase":"PHASE2","title":"The Study of Abatacept in Combination With Etanercept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT00122382","phase":"PHASE3","title":"Remission and Joint Damage Progression in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"Rheumatoid Arthritis","enrollment":1052}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orencia","BMS-188667"],"phase":"phase_3","status":"active","brandName":"Double-blind Abatacept","genericName":"Double-blind Abatacept","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}